Romidepsin

ID: ALA3310505

Chembl Id: CHEMBL3310505

PubChem CID: 11947684

Max Phase: Preclinical

Molecular Formula: C24H36N4O6S2

Molecular Weight: 540.71

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O

Standard InChI:  InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17+,19+,20-/m0/s1

Standard InChI Key:  OHRURASPPZQGQM-QSVHVVLASA-N

Alternative Forms

1. Parent:

   

   ALA3310505

   Romidepsin (FK228, depsipeptide)

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 540.71

Molecular Weight (Monoisotopic): 540.2076

AlogP: 1.43

#Rotatable Bonds: 2

Polar Surface Area: 142.70

Molecular Species: NEUTRAL

HBA: 8

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 10.67

CX Basic pKa:

CX LogP: 1.08

CX LogD: 1.08

Aromatic Rings: 0

Heavy Atoms: 36

QED Weighted: 0.18

Np Likeness Score: 2.22

References

1. Hailu GS, Robaa D, Forgione M, Sippl W, Rotili D, Mai A..  (2017)  Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.,  60  (12): [PMID:28241112] [10.1021/acs.jmedchem.6b01595]

2. Huang L, Lai WH, Zhu L, Li W, Wei L, Lee KH, Xie L, Chen CH..  (2018)  Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor.,  9  (3): [PMID:29541372] [10.1021/acsmedchemlett.8b00012]

3. Diedrich D, Stenzel K, Hesping E, Antonova-Koch Y, Gebru T, Duffy S, Fisher G, Schöler A, Meister S, Kurz T, Avery VM, Winzeler EA, Held J, Andrews KT, Hansen FK..  (2018)  One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.,  158  [PMID:30245402] [10.1016/j.ejmech.2018.09.018]

4. Maruta H, Ahn MR..  (2017)  From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.,  142  [PMID:28814374] [10.1016/j.ejmech.2017.07.043]

5. Brindisi M, Saraswati AP, Brogi S, Gemma S, Butini S, Campiani G..  (2020)  Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.,  63  (1): [PMID:31415174] [10.1021/acs.jmedchem.9b00924]

6. Wan Y, Li Y, Yan C, Yan M, Tang Z..  (2019)  Indole: A privileged scaffold for the design of anti-cancer agents.,  183  [PMID:31536895] [10.1016/j.ejmech.2019.111691]

7. Nguyen W, Jacobson J, Jarman KE, Jousset Sabroux H, Harty L, McMahon J, Lewin SR, Purcell DF, Sleebs BE..  (2019)  Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models.,  62  (10): [PMID:30973727] [10.1021/acs.jmedchem.9b00462]

8. Sangwan R, Rajan R, Mandal PK..  (2018)  HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.,  158  [PMID:30245394] [10.1016/j.ejmech.2018.08.073]

9. Liu X, Currens GC, Xue L, Cheng YQ..  (2019)  Origin and bioactivities of thiosulfinated FK228.,  10  (4): [PMID:31057733] [10.1039/C9MD00060G]

10. Narita K,Matsuhara K,Itoh J,Akiyama Y,Dan S,Yamori T,Ito A,Yoshida M,Katoh T.  (2016)  Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors.,  121  [PMID:27318982] [10.1016/j.ejmech.2016.05.031]

11. Ho TCS,Chan AHY,Ganesan A.  (2020)  Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.,  63  (21.0): [PMID:32608981] [10.1021/acs.jmedchem.0c00830]

12. Zhang K, Liu Z, Yao Y, Qiu Y, Li F, Chen D, Hamilton DJ, Li Z, Jiang S..  (2021)  Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).,  64  (7.0): [PMID:33745280] [10.1021/acs.jmedchem.0c02161]

13. Belayet JB, Beamish S, Rahaman M, Alanani S, Virdi RS, Frick DN, Rahman AFMT, Ulicki JS, Biswas S, Arnold LA, Roni MSR, Cheng EY, Steeber DA, Frick KM, Hossain MM..  (2022)  Development of a Novel, Small-Molecule Brain-Penetrant Histone Deacetylase Inhibitor That Enhances Spatial Memory Formation in Mice.,  65  (4.0): [PMID:35133171] [10.1021/acs.jmedchem.1c01928]

14. Lopes JR, Chiba DE, Dos Santos JL..  (2021)  HIV latency reversal agents: A potential path for functional cure?,  213  [PMID:33540228] [10.1016/j.ejmech.2021.113213]

15. Gediya P, Parikh PK, Vyas VK, Ghate MD..  (2021)  Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.,  216  [PMID:33714914] [10.1016/j.ejmech.2021.113332]

16. Qiu X, Zhu L, Wang H, Tan Y, Yang Z, Yang L, Wan L..  (2021)  From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.,  52  [PMID:34826681] [10.1016/j.bmc.2021.116510]

17. Hill J, Crich D..  (2022)  The N,N,O-Trisubstituted Hydroxylamine Isostere and Its Influence on Lipophilicity and Related Parameters.,  13  (5.0): [PMID:35586423] [10.1021/acsmedchemlett.1c00713]

18. Barone S, Cassese E, Alfano AI, Brindisi M, Summa V..  (2022)  Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.,  65  (4.0): [PMID:35148101] [10.1021/acs.jmedchem.1c02067]

Source

Source(1):

• Scientific Literature